Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-021346
Filing Date
2025-02-14
Accepted
2025-02-14 16:44:44
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 9811
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 73966
  Complete submission text file 0000950170-25-021346.txt   113542
Mailing Address 228 HAMILTON AVENUE, 3RD FLOOR PALO ALTO CA 94301
Business Address 228 HAMILTON AVENUE, 3RD FLOOR PALO ALTO CA 94301 650-798-5495
TCG Crossover GP I, LLC (Filed by) CIK: 0001839947 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A

Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Subject) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-93617 | Film No.: 25630152
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)